INMED PHARMACEUTICALS INC. Impairment of Intangible Assets (Excluding Goodwill)
INMED PHARMACEUTICALS INC. (INM) reported Impairment of Intangible Assets (Excluding Goodwill) of $1.46 million for the 12-month period ending 2026-06-30, per its S-4/A filed 2026-09-09.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill · last filed 2026-09-09
- INMED PHARMACEUTICALS INC. impairment of intangible assets (excluding goodwill) for the quarter ending 2022-06-30 was -$1.82M.
- INMED PHARMACEUTICALS INC. impairment of intangible assets (excluding goodwill) for fiscal 2022 was $200.00K.
| Period end | Impairment of Intangible Assets (Excluding Goodwill) 3 month | Impairment of Intangible Assets (Excluding Goodwill) 9 month | Impairment of Intangible Assets (Excluding Goodwill) 12 month |
|---|---|---|---|
| 2026-06-30 | $1.46M S-4/A · filed 2026-09-09 | ||
| 2022-06-30 | -$1.82M derived: 10-K 12 month − 10-Q 9 month · filed 2023-09-29 | $200.00K 10-K · filed 2023-09-29 | |
| 2022-03-31 | $2.02M 10-Q · filed 2022-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |